{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:24:17Z","timestamp":1791588257889,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013915","name":"King's College London EPSRC Centre for Doctoral Training in Medical Imaging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bmcl.2021.128044","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T02:58:13Z","timestamp":1618801093000},"page":"128044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4141-9663","authenticated-orcid":false,"given":"Jennifer D.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3349-7346","authenticated-orcid":false,"given":"Michelle T.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-3808","authenticated-orcid":false,"given":"Thomas R.","family":"Eykyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Andrew","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-5183","authenticated-orcid":false,"given":"Agostino","family":"Cilibrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Hider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Blower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2021.128044_b0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00259-019-04643-7","article-title":"The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer","volume":"47","author":"Kulkarni","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128044_b0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-018-4203-0","article-title":"Clinical impact of 68 Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bmcl.2021.128044_b0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.117.192625","article-title":"68 Ga-PSMA PET\/CT impact on prostate cancer management","volume":"59","author":"Afaq","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128044_b0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68 Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128044_b0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128044_b0030","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.117.191882","article-title":"68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room-temperature, 1-step kit-based radiolabeling","volume":"58","author":"Young","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bmcl.2021.128044_b0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2967\/jnumed.117.199554","article-title":"Cold kit PSMA PET imaging: phase I study of 68Ga-THP-PSMA PET\/CT in patients with prostate cancer","volume":"59","author":"Hofman","year":"2018","journal-title":"J Nucl Med"},{"issue":"20","key":"10.1016\/j.bmcl.2021.128044_b0040","first-page":"1","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study","volume":"6736","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bmcl.2021.128044_b0045","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2967\/jnumed.119.234054","article-title":"Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics","volume":"60","author":"Rahbar","year":"2019","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128044_b0050","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmcl.2021.128044_b0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pros.10319","article-title":"Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene","volume":"58","author":"O\u2019Keefe","year":"2004","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128044_b0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents","volume":"47","author":"Kozikowski","year":"2004","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128044_b0065","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2174\/0929867013372797","article-title":"Design of NAALADase inhibitors: a novel neuroprotective strategy","volume":"8","author":"Jackson","year":"2001","journal-title":"Curr Med Chem"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128044_b0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd1903","article-title":"NAAG peptidase inhibitors and their potential for diagnosis and therapy","volume":"4","author":"Zhou","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"10.1016\/j.bmcl.2021.128044_b0075","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1021\/bi900220s","article-title":"Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods","volume":"48","author":"Klus\u00e1k","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2021.128044_b0080","doi-asserted-by":"crossref","unstructured":"J. Pavlicek J. Ptacek C. Barinka Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme Curr Med Chem. 19 9 2012 1300 1309 CDT-EPUB-20120203-004 [pii].","DOI":"10.2174\/092986712799462667"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128044_b0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1162\/153535002320162750","article-title":"11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase)","volume":"1","author":"Pomper","year":"2002","journal-title":"Mol Imaging"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128044_b0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.7150\/thno.13448","article-title":"Design of internalizing PSMA-specific glu-ureido-based radiotherapeuticals","volume":"6","author":"W\u00fcstemann","year":"2016","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128044_b0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.bmcl.2021.128044_b0100","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Chen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128044_b0105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128044_b0110","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1021\/mp9000712","article-title":"Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents","volume":"6","author":"Kularatne","year":"2009","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128044_b0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1107\/S174430910700379X","article-title":"A high-resolution structure of ligand-free human glutamate carboxypeptidase II","volume":"63","author":"Barinka","year":"2007","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"issue":"16","key":"10.1016\/j.bmcl.2021.128044_b0120","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1111\/j.1742-4658.2009.07152.x","article-title":"Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III","volume":"276","author":"Hlouchova","year":"2009","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128044_b0125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/febs.13557","article-title":"Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities","volume":"283","author":"Novakova","year":"2016","journal-title":"FEBS J"},{"issue":"24","key":"10.1016\/j.bmcl.2021.128044_b0130","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J Med Chem"},{"issue":"23","key":"10.1016\/j.bmcl.2021.128044_b0135","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1016\/j.bmc.2007.07.028","article-title":"The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen","volume":"15","author":"Wu","year":"2007","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.bmcl.2021.128044_b0140","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1021\/jm020515w","article-title":"Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II\u202f: discovery of an orally active GCP II inhibitor","volume":"46","author":"Majer","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128044_b0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2016.04.010","article-title":"The biological inorganic chemistry of zinc ions","volume":"611","author":"Kr\u0119\u017cel","year":"2016","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128044_b0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.optmat.2008.05.002","article-title":"Influence of glycine on the nonlinear optical (NLO) properties of zinc (tris) thiourea sulfate (ZTS) single crystal","volume":"31","author":"Dhumane","year":"2008","journal-title":"Opt Mater (Amst)"},{"issue":"49","key":"10.1016\/j.bmcl.2021.128044_b0155","doi-asserted-by":"crossref","first-page":"38302","DOI":"10.1074\/jbc.M005957200","article-title":"Redox switch of Hsp33 has a novel zinc-binding motif","volume":"275","author":"Jakob","year":"2000","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128044_b0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1096\/fasebj.9.8.7768350","article-title":"Zinc Fingers","volume":"9","author":"Klug","year":"1995","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128044_b0165","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1021\/jo1001593","article-title":"A concise synthesis of substituted thiourea derivatives in aqueous medium","volume":"75","author":"Maddani","year":"2010","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmcl.2021.128044_b0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF01516801","article-title":"Vorl\u00e4ufige mittheilung \u00fcber glutamins\u00e4ure und pyrrol","volume":"3","author":"Haitinger","year":"1882","journal-title":"Monatshefte f\u00fcr Chemie und verwandte Teile anderer Wissenschaften."},{"issue":"2","key":"10.1016\/j.bmcl.2021.128044_b0175","first-page":"288","article-title":"Pyroglutamic acid: throwing light on a lightly studied metabolite","volume":"102","author":"Kumar","year":"2012","journal-title":"Curr Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128044_b0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2191-219X-4-13","article-title":"Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)","volume":"4","author":"Kampmeier","year":"2014","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.bmcl.2021.128044_b0185","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128044_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061007","article-title":"Comparability of Mixed IC50 Data - A Statistical Analysis","volume":"8","author":"Kalliokoski","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2021.128044_b0195","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1039\/jr9580002551","article-title":"A detailed refinement of the crystal and molecular structure of thiourea","author":"Kunchur","year":"1958","journal-title":"J Chem Soc"},{"key":"10.1016\/j.bmcl.2021.128044_b0200","doi-asserted-by":"crossref","unstructured":"P. Vaughn J. Donahue The structure of urea. Interatomic distances and resonance in urea and related compounds Acta Crystallogr. 1952;(5):530\u2013535. 10.1107\/S0365110X52001477.","DOI":"10.1107\/S0365110X52001477"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128044_b0205","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/prot.21536","article-title":"Analysis of zinc-ligand bond lengths in metalloproteins: Trends and patterns","volume":"69","author":"Tamames","year":"2007","journal-title":"Proteins"}],"updated-by":[{"DOI":"10.1016\/j.bmcl.2021.128231","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000}}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21002705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21002705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:20:22Z","timestamp":1630023622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21002705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"alternative-id":["S0960894X21002705"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128044","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bmcl.2021.128231","asserted-by":"object"}]},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128044"}}